Suhail Dohad, MD
Interventional Cardiology · Beverly Hills, CANPI 1730151085
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Penumbra, Inc. at 45.8% of the total. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,479 payments — averaging $541.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$367K
- Boston Scientific$236K
- Abbott$141K
- Shockwave Medical, Inc$13K
- Johnson & Johnson$11K
- Philips North America LLC$11K
- plus $23K from 41 others
Across 186 payments — averaging $9564.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$701K
- Boston Scientific$427K
- Penumbra, Inc.$332K
- Abbott$145K
- Shockwave Medical, Inc$81K
- M.a. Med Alliance S.A.$73K
- plus $21K from 3 others
What the payments were for
- Consulting fees$170,85221%
- Speaking & faculty fees$431,95054%
- Grants$3500%
- Travel & lodging$122,19315%
- Food & beverage$76,22210%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$297,332
- Indigo$66,185
- Xience V coronary stent system$65,622
- GENERAL VASCULAR ACCESS$41,749
- CROSSBOSS$40,486
- Diamondback Coronary$18,356
- XIENCE SKYPOINT$14,667
- GENERAL - THERAPIES$14,311
- HI-TORQUE BALANCE$13,500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$11,564
- XARELTO$10,786
- GENERAL VASCULAR INTERVENTION$8,500
- Dragonfly OCT$8,246
- OPTIS$8,063
- RUBY Coil$7,648
- Spectranetics Undiv$4,800
- XIENCE V$3,419
- GUIDEZILLA$3,000
- WOLVERINE CORONARY CUTTING BALLOON$2,892
- Impella$2,472
How this compares
$801,586 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 130 | $127,436 |
| JardianceEmpagliflozin | 134 | $115,994 |
| XareltoRivaroxaban | 126 | $109,094 |
| Repatha SureclickEvolocumab | 104 | $91,700 |
| EliquisApixaban | 59 | $66,443 |
| FarxigaDapagliflozin Propanediol | 49 | $53,917 |
| BrilintaTicagrelor | 73 | $46,095 |
| OzempicSemaglutide | 32 | $36,767 |
| WegovySemaglutide | 16 | $20,466 |
| Praluent PenAlirocumab | 17 | $11,155 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 17 | $5,144 |
| CrestorRosuvastatin Calcium | 13 | $5,031 |
| Rosuvastatin Calcium | 295 | $4,685 |
| Nebivolol Hcl | 35 | $4,073 |
| Tadalafil | 20 | $4,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $171 | $127,436130 claims |
| Boehringer IngelheimJardiance | $22 | $115,994134 claims |
| Johnson & JohnsonXarelto | $11,043 | $109,094126 claims |
| AstraZenecaFarxiga, Brilinta, Crestor | $61 | $105,043135 claims |
| PfizerEliquis | $151 | $66,44359 claims |
| Novo NordiskOzempic, Wegovy | $25 | $57,23348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Beverly Hills
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
- Mitul PatelSan Diego$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.